RxDoctor Payments Data

Phillip Joseph, MD

Pulmonary Disease · New Haven, CTNPI 1649530007

Payments from drug & device makers

What this record shows

United Therapeutics Corporation accounts for 91.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $2,061 and has fallen 74.5% since, to $525 in 2025.

$3,965in general payments, 2019–2025

Across 30 payments — averaging $132.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$4K
  • Bayer$220
  • Actelion Pharmaceuticals US, Inc.$85
  • Sandoz$17
$483,624in research payments, 2019–2025

Across 17 payments — averaging $28,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$399K
  • Astrazeneca UK Limited$56K
  • Janssen Research & Development, LLC$28K

What the payments were for

  • Consulting fees$2,04552%
  • Food & beverage$1,92048%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,965 in reported general payments places this provider in the 70th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$65,532
Medicare patients
221
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil113$3,375,791
OpsumitMacitentan42$577,265
AdempasRiociguat24$331,950
RemodulinTreprostinil Sodium43$326,117
WinrevairSotatercept-Csrk15$213,118
Orenitram ErTreprostinil Diolamine52$142,480
Ambrisentan47$137,001
Tadalafil87$113,119
Sildenafil Citrate168$39,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$32,411
Spiriva RespimatTiotropium Bromide25$16,317
XareltoRivaroxaban13$16,108
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,409
Tramadol Hcl40$550
Fluticasone Propionate20$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$85$577,26542 claims
BayerAdempas$220$331,95024 claims
United Therapeutics CorporationRemodulin$3,643$326,11743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →